Cellebrite (CLBT)

• Market cap: $4.84B
• 1 day: 5.78%
• 5 days: 11.76%
• 1 month: 18.53%
• 3 months: 29.43%
• 6 months: 87.67%
• Year to date: 167.14%
• 1 year: 174.97%
• 5 years: 119.71%
• 10 years: 119.71%

About: Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.

Employees: 1,008

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

261% more call options, than puts

Call options by funds: $12.5M | Put options by funds: $3.45M

84% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 19

67% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]

60% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 45

44% more capital invested

Capital invested by funds: $1.07B [Q2] → $1.55B (+$476M) [Q3]

11% more funds holding

Funds holding: 147 [Q2] → 163 (+16) [Q3]

0.48% more ownership

Funds ownership: 43.76% [Q2] → 44.23% (+0.48%) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21 7% downside
• Avg. target: $23 2% upside
• High target: $24 7% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Brian Essex 61% 1-year accuracy 17 / 28 met price target	7% upside $24	Overweight Maintained	16 Dec 2024
Craig-Hallum Jeff Van Rhee 69% 1-year accuracy 11 / 16 met price target	7% upside $24	Buy Maintained	7 Nov 2024
Needham Mike Cikos 56% 1-year accuracy 55 / 99 met price target	7% downside $21	Buy Maintained	7 Nov 2024
TD Cowen Shaul Eyal 88% 1-year accuracy 14 / 16 met price target	2% upside $23	Buy Maintained	23 Sept 2024